Hims Delivered 173% Returns Over Five Years but Recent Buyers Face 50% Losses
Hims & Hers Health (NYSE: HIMS) went public in January 2021 through a SPAC merger, positioning itself as a multi-specialty telehealth platform offering prescription medications, mental health support, and personal care products.
HIMS vs. TDOC: Which Telehealth Stock Looks More Compelling?
Hims & Hers and Teladoc Health are expanding virtual care in different ways, but which telehealth platform looks more compelling right now? Let's dive in.
Hims & Hers Expands Subscription-Led Care as Platform Engagement Grows
HIMS deepens its subscription-led model with new care verticals, diagnostics and global expansion to boost retention.
Hims & Hers Health, Inc. (HIMS) Is a Trending Stock: Facts to Know Before Betting on It
Zacks.com users have recently been watching Hims & Hers Health (HIMS) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Hims & Hers Scales Technology-Driven Care as Profitability Evolves
HIMS scales personalized care, expands globally and invests in technology as it balances growth with evolving profitability.
Hims & Hers Expands Weight-Management Program to the United Kingdom
HIMS expands its Weight Loss Program to the United Kingdom, bringing personalized, doctor-designed care and broader access to obesity treatments.
Investors Heavily Search Hims & Hers Health, Inc. (HIMS): Here is What You Need to Know
Recently, Zacks.com users have been paying close attention to Hims & Hers Health (HIMS). This makes it worthwhile to examine what the stock has in store.
Hims & Hers Expands Its Technology-Driven Personalized Virtual Care
HIMS expands its tech-driven care with new diagnostics, hormonal treatments, and a Canada launch via Livewell.
Hims and Hers to offer weight-loss treatments in UK
Online telehealth company Hims and Hers Health is launching its weight-loss membership and treatment plans in the United Kingdom which will include drugs like Novo Nordisk's Wegovy, the company said on Wednesday.
Hims & Hers Plunges 29.1% in 6 Months: Time to Hold the Stock or Sell?
HIMS expands into Canada and Europe while facing regulatory hurdles and execution risks in weight-loss care.
A New Market, A New Catalyst: Assessing Hims & Hers' Canadian Opportunity
Hims & Hers Health expands into Canada via Livewell acquisition, targeting a large, underserved weight-loss market. Canadian entry leverages local leadership and expertise, aiming to replicate successful European expansion and accelerate subscriber growth. GLP-1 weight-loss treatments drive revenue potential but introduce margin pressure and cost volatility, creating both opportunity and structural risk.
HIMS Stock Jumps After Buyout Deal, Boosts Blood Collection Efficiency
Hims & Hers is set to acquire YourBio Health, adding bladeless microneedle tech to transform the blood collection experience.
